Cleerly is creating a new standard of care for heart disease. Through its FDA-cleared, value-based diagnostic solutions driven by artificial and machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Rather than studying surrogates of the number one killer, heart disease, Cleerly is shifting the care paradigm from treating late-stage symptoms to proactively identifying early stages of disease when its progression can be more easily prevented.